Endometrium-derived mesenchymal stem cells suppress progression of endometrial cancer via the DKK1-Wnt/β-catenin signaling pathway.

Yuhui XuJiali HuQiaoying LvChenyi ShiMengdi QiuLiying XieWei LiuBingyi YangWeiwei ShanYali ChengBing ZhaoXiao-Jun Chen

Published in: Stem cell research & therapy (2023)

The eMSCs, but not AD-MSCs or UC-MSCs, could suppress the malignant behaviors of EC both in vivo and in vitro via inhibiting the Wnt/β-catenin signaling pathway by secreting DKK1. The combination of eMSCs and MPA effectively inhibited EC growth, indicating that eMSCs may potentially be a new therapeutic strategy for young EC patients desiring for fertility preservation.

Keyphrases

endometrial cancer
end stage renal disease
mesenchymal stem cells
cell proliferation
stem cells
ejection fraction
newly diagnosed
chronic kidney disease
umbilical cord
peritoneal dialysis
signaling pathway
prognostic factors
young adults
childhood cancer